Enhanced

Checkout starts with a short health questionnaire covering symptoms, goals, and history. A licensed clinician then reviews bloodwork, history, and goals to decide whether tirzepatide or semaglutide is a medically appropriate fit. If prescribed, the patient begins a personalized, titrated protocol with clinician check-ins included; tirzepatide’s titration schedule is typically slower than semaglutide’s, aimed at finding an effective dose without unnecessary GI side effects.

Enhanced describes tirzepatide as activating both GLP-1 and GIP receptor pathways, versus semaglutide’s single GLP-1 pathway, and positions tirzepatide for patients who haven’t seen the results they wanted on a single-pathway GLP-1. Enhanced’s own pages say most patients notice quieter food noise and reduced cravings within the first few weeks of titration, with visible weight changes typically becoming noticeable over the first two to three months; the company states individual results vary and eligibility is determined case by case.

Beyond its two core GLP-1 protocols, Enhanced sells a menu of add-on compounded peptides patients can build into their protocol, including NAD+ (from $143 a month), GHK-Cu copper peptide (from $119 a month), and Sermorelin (from $172 a month), plus separate Hormones, Longevity & Recovery, and Sexual Performance pathways and a line of non-prescription daily supplements.

The path to treatment is a short online questionnaire followed by clinician review, with no in-person visit required. Dosing and titration schedules are set and adjusted by the assigned clinician rather than left for the patient to figure out, and the protocol is described as an ongoing cycle that’s adjusted over time rather than a fixed, one-time prescription.

Enhanced’s protocol includes ongoing clinician monitoring and check-ins as part of the base price. We didn’t find a stated live chat or phone support option for the weight-loss protocol on the pages we reviewed; account and telehealth questions appear to route through a dedicated telehealth portal and a general support email address.

Enhanced states its tirzepatide and semaglutide are compounded by a licensed 503A/503B U.S. pharmacy, and its site carries the standard disclosure that compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. Eligibility for either treatment is determined by a licensed clinician based on medical history, laboratory testing, and clinical judgment, and Enhanced states not all patients qualify for treatment.